Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
Investing.com - Diaceutics PLC (AIM:DXRX) shares rose 0.9% after the precision medicine commercialization partner reported strong first-half 2025 results, with revenue growth of 22% on a constant currency basis to £14.6 million and a return to adjusted EBITDA profitability.
The company, which provides data analytics and commercialization solutions to pharmaceutical and biotech firms, reported H1 adjusted EBITDA of £0.1 million compared to a £0.9 million loss in the same period last year.
This marks an important milestone as Diaceutics confirmed it remains on track to deliver full-year profitability for 2025.
Revenue growth was driven by increasing adoption of the company’s DXRX platform, with recurring revenue now representing 61% of total H1 revenues, up from 55% a year earlier.
Annual Recurring Revenue (ARR) increased 16% to £16.4 million, while the company’s order book grew 14% to £31.7 million, with £9.0 million already contracted for delivery in the second half of 2025.
"I am extremely pleased to report another period of strong operational and commercial execution, marked by double-digit organic revenue growth, expanding customer adoption and increased recurring revenue visibility," said Ryan Keeling, Diaceutics’ Chief Executive Officer.
"The success of our current strategy and financial strength, and the sustained positive momentum in 2025 to date, serve to validate our growth strategy and provide us with confidence that our profitability targets for 2025 are on track to be delivered as we continue to grow."
The company reported a 17% increase in the number of therapeutic brands it works with, reaching 74 in H1 2025 compared to 63 in the same period last year. Diaceutics also secured a new enterprise-wide agreement, bringing its total to eight, representing £10.1 million in ARR.
Despite a challenging environment for the pharmaceutical industry, particularly in the US market, Diaceutics maintained a strong balance sheet with no debt and cash of £10.4 million at the end of June 2025.
The company expects to maintain its momentum in the second half of the year, with continued focus on deeper customer engagement and leveraging its enhanced technologies to deliver operational leverage.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.